BMO Capital raised the firm’s price target on BrightSpring Health (BTSG) to $70 from $60 and keeps an Outperform rating on the shares. The firm has leveraged AI to map and quantify all recent and upcoming expected generic conversions to conclude that the majority of the generic opportunity still lies ahead, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTSG:
- BrightSpring: Durable Above-Peer Growth Outlook Drives Price Target Increase to $70 and Reiterated Buy Rating
- BrightSpring Earnings Call Highlights Growth Amid Headwinds
- CMS announces six-month hospice and home health agency enrollment moratoria
- BrightSpring Health price target raised to $66 from $63 at BofA
- BrightSpring Health price target raised to $62 from $48 at Morgan Stanley